相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current Microsatellite Instability Testing in Management of Colorectal Cancer
Belinda L. Sun
CLINICAL COLORECTAL CANCER (2021)
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Functional outcomes of surgery for colon cancer: A systematic review and meta-analysis
Sanne J. Verkuijl et al.
EJSO (2021)
PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification
Pablo Azcue et al.
CANCERS (2021)
Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
Manish Pratap Singh et al.
GENES & DISEASES (2021)
Colonic Adenocarcinomas Harboring NTRK Fusion Genes A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature
Jerzy Lasota et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
Jane Thomas et al.
CLINICAL COLORECTAL CANCER (2020)
KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the β-catenin/STT3 signaling pathway
Zhiyan Ruan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
Emilie Picard et al.
FRONTIERS IN IMMUNOLOGY (2020)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study
Kai-Keen Shiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
Cytoskeletal Control and Wnt Signaling-APC's Dual Contributions in Stem Cell Division and Colorectal Cancer
M. Angeles Juanes
CANCERS (2020)
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients
Jacqueline Wyss et al.
CLINICAL COLORECTAL CANCER (2019)
Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials
E. Fontana et al.
ANNALS OF ONCOLOGY (2019)
Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin-β-catenin-vinculin axis
Ipsita Pal et al.
CANCER LETTERS (2019)
Prognostic role of glycolysis for cancer outcome: evidence from 86 studies
Min Yu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer
Matthew J. Cecchini et al.
HUMAN PATHOLOGY (2019)
Squalene Epoxidase Correlates E-Cadherin Expression and Overall Survival in Colorectal Cancer Patients: The Impact on Prognosis and Correlation to Clinicopathologic Features
Joo Heon Kim et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Downregulation of lncRNA AWPPH inhibits colon cancer cell proliferation by downregulating GLUT-1
Jie Bai et al.
ONCOLOGY LETTERS (2019)
CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma
Khadija Slik et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Low expression of MUC2 is associated with longer disease-free survival in patients with colorectal carcinoma
Jaudah Al-Maghrabi et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2019)
Molecular subtyping improves prognostication of Stage 2 colorectal cancer
Rachel Purcell et al.
BMC CANCER (2019)
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer
Aya Nishiuchi et al.
CANCERS (2019)
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
Zefeng Shen et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
E-cadherin and NEDD9 expression in primary colorectal cancer, metastatic lymph nodes and liver metastases
Petra Jurcic et al.
ONCOLOGY LETTERS (2019)
Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis
Gianluca Tomasello et al.
CLINICAL COLORECTAL CANCER (2018)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
Jarle Bruun et al.
MOLECULAR ONCOLOGY (2018)
Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
Chao Li et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2018)
Colorectal Cancers: An Update on Their Molecular Pathology
Kentaro Inamura
CANCERS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database
Mohamed E. Salem et al.
EUROPEAN JOURNAL OF CANCER (2018)
Differential expression of mucin 1 and mucin 2 in colorectal cancer
Aldona Kasprzak et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors
Jianchun Duan et al.
THORACIC CANCER (2018)
LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer
M Chalabi et al.
ANNALS OF ONCOLOGY (2018)
Sodium-glucose cotransporters: new targets of cancer therapy?
Ivana Vrhovac Madunic et al.
ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY (2018)
Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts
Torben Frostrup Hansen et al.
BRITISH JOURNAL OF CANCER (2018)
Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
Anne Trinh et al.
CLINICAL CANCER RESEARCH (2017)
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Ben Zhao et al.
ONCOTARGET (2017)
Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics
Haipeng Wang et al.
ONCOLOGY LETTERS (2017)
E-cadherin: A potential biomarker of colorectal cancer prognosis (Review)
Niki Christou et al.
ONCOLOGY LETTERS (2017)
Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer
Ben Y. Zhang et al.
CLINICAL COLORECTAL CANCER (2017)
CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification
C. Pilati et al.
ANNALS OF ONCOLOGY (2017)
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Rodrigo Dienstmann et al.
NATURE REVIEWS CANCER (2017)
CDX2 downregulation is associated with poor differentiation and MMR deficiency in colon cancer
J. Olsen et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2016)
Differences between colon and rectal cancer in complications, short-term survival and recurrences
Max P. L. van der Sijp et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2016)
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Piero Dalerba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
Johannes Betge et al.
VIRCHOWS ARCHIV (2016)
Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012
Martin D. Berger et al.
ONCOTARGET (2016)
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of NSABP C-O7/NRG Oncology Randomized Clinical Trial
Nan Song et al.
JAMA ONCOLOGY (2016)
Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis
L. De Smedt et al.
BRITISH JOURNAL OF CANCER (2015)
Rectal and colon cancer: Not just a different anatomic site
K. Tamas et al.
CANCER TREATMENT REVIEWS (2015)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients
Jeong Mo Bae et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature
Mrunal Kesari et al.
INDIAN JOURNAL OF GASTROENTEROLOGY (2015)
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
Paul Roepman et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
Felipe De Sousa E Melo et al.
NATURE MEDICINE (2013)
Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma
Adam Elzagheid et al.
TUMOR BIOLOGY (2013)
Differential mucin phenotypes and their significance in a variation of colorectal carcinoma
Yasuo Imai et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Clinical Significance of Serum Soluble E-cadherin in Colorectal Carcinoma
Yoshinaga Okugawa et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Loss of E-cadherin and MUC2 Expressions Correlated with Poor Survival in Patients with Stages II and III Colorectal Carcinoma
Haeyoun Kang et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker
Katia C. Carvalho et al.
CLINICS (2011)
Clinicopathologic significance of GLUT1 expression and its correlation with Apaf-1 in colorectal adenocarcinomas
Young Jin Jun et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Glucose transporter Glut-1 is detectable in pen-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays
Rachel Airley et al.
ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER (2010)
Cdx2 regulates patterning of the intestinal epithelium
Stephanie Grainger et al.
DEVELOPMENTAL BIOLOGY (2010)
Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer
Yoshifumi Baba et al.
CLINICAL CANCER RESEARCH (2009)
Molecular classification and correlates in colorectal cancer
Shuji Ogino et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics
Rachel E. Airley et al.
CHEMOTHERAPY (2007)
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
J. R. Jass
HISTOPATHOLOGY (2007)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients
C Wilmanns et al.
CLINICAL & EXPERIMENTAL METASTASIS (2004)
Glucose transporter-1 (GLUT-1):: a potential marker of prognosis in rectal carcinoma?
R Cooper et al.
BRITISH JOURNAL OF CANCER (2003)
E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells
I Thievessen et al.
BRITISH JOURNAL OF CANCER (2003)
CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin - An immunohistochemical survey of 476 primary and metastatic carcinomas
RW Werling et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/Extracellular Signal-regulated Kinase cascade and Sp1
M Perrais et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features
M Sakashita et al.
EUROPEAN JOURNAL OF CANCER (2001)
分享论文
